anoth year acceler
strong result guidanc rais driven medsurg
mako momentum continu look like anoth year
make look easi organ sale growth beat estim
preview impli bp momentum acceler medsurg
driver organ growth pt higher estim drive
addit pt corpor growth ortho rel line vs mse
mako momentum continu robust spine neurotech organ
growth miss estim pt impli pt momentum
deceler discuss follow strong perform
organ rais organ growth guidanc second consecut
quarter vs prior deliv top end rang
would mark seven consecut year organ growth acceler
margin bp light estim medsurg mix also
includ bp acquisit dilut ep
estim albeit mainli driven tax vs mse non-op vs
mse ep guidanc also rais midpoint
view posit given uncommon rais bottom line
quarterli beat
upsid medsurg durabl discuss double-digit
medsurg growth possibl year perform combin
broader busi momentum leav us increasingli posit
likelihood instrument sale organ materi stronger
consensu driven benefit split sale forc power
tool wast manag manag commentari suggest elev
growth seen like sustain model
growth vs within endoscopi organ growth includ
doubl digit growth compani video busi camera start
ramp expect substanti contribut histor investor
reward medsurg out-performance busi
view cyclic discuss view flaw see
given segment grown averag annual ceo kevin lobo
faster corpor averag busi model
transform becom diversifi durabl see momentum
continu potenti upsid base year two
stronger physio launch first new lifepak year
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
first medsurg bed launch year
growth stabl momentum basi wherea ex us growth
impli pt momentum deceler result thu
far us recon market appear stabl model impli bp
momentum acceler howev adequ judgement made
follow zimmer biomet result tomorrow relat mako
place system global in-lin estim procedur growth
remain robust mako tka procedur perform repres
y/i q/q vs us knee penetr rate continu improv
us knee perform mako compar
us hip manag commentari notabl posit hip acceler
uptak compani trident cup combin
increas mako hip util drove doubl digit procedur growth
competit front see zimmer biomet rosa immin risk
mako/cementless rosa limit launch like focu
zimmer biomet loyal account see
neurotech spine focu second half spine area
concern head year given integr preview spine
weak bulk cross-train sell set occur
result pro-forma growth signal improv vs
manag remain confid mid singl digit pro-forma growth
requir pro-forma growth neuro busi
consist perform growth mark nine consecut quarter
doubl digit growth howev momentum deceler pt sens us
market may soft know sure competitor report
anticip acceler given larg bore
aspir cathet launch late surpass launch gradual
believ see acceler
model move rais top-line growth expect
base medsurg pt ortho bp slightli off-set
spine neuro pt remain confid abil deliv top
end organ growth guidanc driven medsurg mako momentum
discuss remain cautiou spine near-term margin
estim remain rel unchang bp forecast expans y/i
although expect manag deliv underli expans bp
adjust acquisit dilut discuss prefer addit
leverag given margin gener kept pace sale
improv kevin lobo tenur cautious optimist
improv margin pictur beyond given compani
earli stage share servic opportun erp system ration
ceo meet recap addit detail cost transform
opportun ep estim move higher nearli
driven top-line drop-through
anoth year acceler look like remain overweight
discuss perform predic abil
maintain peer organ growth provid upsid earn floor
clear compani deliv organ growth acceler
follow two consecut quarter guidanc rais ep guidanc
rais step right direct toward consist low mid
teen earn growth remain confid abil deliv top
end organ growth ep guidanc remain overweight
price target base ep reflect four turn premium
larg cap peer justifi growth leverag balanc sheet
outlook tie growth leverag mako
outlook tie growth leverag mako
deriv base case scenario multipl four turn
premium peer reflect above-p top-
line growth divers revenu opportun leverag
mako progress faster expect execut high-return
deal organ growth acceler aid continu share gain recon
driven mako progress util balanc sheet drive sharehold
growth leverag balanc sheet drive upsid organ sale growth
leverag earn continu invest execut mako
plan show commit return receiv premium
multipl strong balanc sheet
organ growth trend toward wamgr margin progress stall growth
slow toward mid-singl digit level initi drive leverag prove
unsuccess given price pressur execut deal
perform predic
manag abil maintain above-p
organ growth execut plan
oper ep upsid capit
deploy continu uptak mako
convict earn floor driven
bp annual underli margin
improv clear debunk critic
robot greatest opportun
increas knee satisfact rate drive
recon growth bp growth yield
bp total top-lin growth
bp ep growth
hospit capital-expenditure expos
hospit capital-expenditure expos
volatil bed segment
mako help drive pt share
recon market given year drive pt
corpor growth
capit deploy buyback
chang orthoped environ
progress transform
risk achiev price
lower expect growth orthoped
competit ortho recon robot
slower growth hospit capit spend
million except ep
million
sale
sale
sale
sale
sale
sale
exhibit stryker chang model
neurotechnolog spine
good sold
current matur long-term debt
addit paid capit
chang oper asset liabil
net provid oper activ
purchas market secur
proce sale market sec
purchas pp
net use invest activ
proce issuanc debt
repay debt
proce option excercis
repurchas common stock
effect exchang rate ce
net chang
equival bop
equival eop
